8-K: Elevance Health Q1 2026 Earnings Beat, Guidance Raised

Elevance Health reported strong first quarter 2026 results, exceeding expectations and leading to an increase in full-year adjusted EPS guidance.

Summary

• Elevance Health reported first quarter 2026 operating revenue of $49.5 billion, a 1.5% increase year-over-year.
• Diluted EPS was $8.00, with adjusted diluted EPS at $12.58, driven by strong operating results and non-recurring investment income.
• The company raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75.
• Full-year 2026 diluted EPS guidance is projected to be at least $19.85, including an estimate for the CMS matter.
• Operating cash flow for Q1 2026 was $4.3 billion, an increase of $3.3 billion year-over-year.
• Elevance Health returned $1.5 billion to shareholders in Q1 2026 through share repurchases and dividends.
• A significant accrual of $935 million was made for a potential exposure related to a CMS notice concerning historical Medicare Advantage risk adjustment data.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with better-than-expected results and raised guidance, despite the significant accrual for the CMS matter.

Positives

• First quarter results exceeded expectations, driven by underlying business strength and improving claims experience.
• Full-year adjusted EPS guidance was raised to at least $26.75, reflecting increased visibility and business strength.
• Operating revenue increased by 1.5% to $49.5 billion in Q1 2026.
• Operating cash flow increased significantly to $4.3 billion in Q1 2026.
• Capital returned to shareholders in Q1 2026 totaled $1.5 billion.
• Carelon segment revenue grew 7.9% to $18.0 billion, driven by Carelon Services and CarelonRx.
• Health Benefits segment revenue grew 2.6% to $42.5 billion, driven by higher premium yields.

Negatives

• Benefit expense ratio increased by 40 basis points to 86.8%, reflecting elevated medical cost trends in Medicaid.
• Operating gain for the Health Benefits segment decreased by 2.7% year-over-year due to higher medical costs in Medicaid.
• Operating gain for the Carelon segment declined by 3.8% year-over-year due to lower health plan membership and investments.
• Total medical membership decreased by 0.9% year-over-year, with notable declines in Medicare Advantage and Employer Group risk-based membership.
• A substantial accrual of $935 million was recorded for a potential CMS exposure, impacting operating expenses.

Risks

• Trends in healthcare costs and utilization rates.
• Reduced enrollment in key programs like Medicare Advantage and Medicaid.
• Impact of new or changes in federal, state, and international laws and regulations impacting healthcare.
• Risks associated with cyber-attacks or other privacy/data security incidents.
• Potential for negative changes in healthcare product mix.
• Costs and liabilities associated with litigation, government investigations, audits, or reviews.
• Intense competition to attract and retain employees.

Future Outlook

Full-year 2026 diluted EPS guidance is projected to be at least $19.85, including an estimate for the CMS matter. Full-year 2026 adjusted diluted EPS guidance has been raised to at least $26.75, supported by underlying business strength, cost reduction actions, and increased visibility. Full-year 2026 operating cash flow is reaffirmed at least $5.5 billion.

Management Comments

• "Our first quarter results exceeded expectations, reflecting underlying business strength and improving claims experience."
• "We are raising our full-year adjusted EPS guidance, supported by greater visibility into the balance of the year."
• "Our actions are driving more consistent performance and position Elevance Health for continued improvement over time."

Industry Context

StockSavvy.ai notes that Elevance Health's Q1 2026 results demonstrate resilience in a challenging healthcare landscape, with strategic actions like cost reduction and business repositioning showing positive early signs. The significant accrual for the CMS matter highlights the ongoing regulatory scrutiny faced by major health insurers.

Comparison to Industry Standards

• Elevance Health's Q1 2026 operating revenue growth of 1.5% is modest compared to some high-growth tech sectors but is typical for large, established health insurers.
• The adjusted diluted EPS of $12.58 exceeds analyst expectations, indicating strong operational execution relative to peers.
• The benefit expense ratio of 86.8% is within the expected range for the industry, though the increase reflects specific pressures in Medicaid, a segment where many insurers are facing challenges.
• The company's focus on cost reduction and operational efficiency aligns with broader industry trends aimed at improving margins amidst rising healthcare costs.

Legal Proceedings

• Potential exposure related to historical Medicare Advantage risk adjustment data concerning a CMS notice dated February 27, 2026, for which a $935 million accrual has been made.

Stakeholder Impact

• Shareholders: Benefit from increased full-year EPS guidance and continued capital return through dividends and share repurchases.
• Employees: May be impacted by business optimization charges and efforts to enhance organizational structure.
• Customers: May experience impacts from membership mix adjustments and ongoing efforts to manage healthcare costs.
• Regulators (CMS): The company has made a significant accrual related to a CMS notice, indicating ongoing interaction and potential financial implications.

Next Steps

• Continue to monitor the financial impact of the CMS matter.
• Execute on strategies to reduce medical costs and improve performance.
• Invest in clinical, operational, and administrative workflows for long-term growth.
• Manage membership mix for sustainable performance.
• Pay second quarter 2026 dividend on June 25, 2026.

Key Dates

Recommendation

While the Q1 results exceeded expectations and guidance was raised, the significant accrual for the CMS matter introduces uncertainty. The company's ability to manage this exposure and its impact on future earnings warrants a cautious 'hold' stance until further clarity emerges.

Keywords

Elevance Health, 8-K, Quarterly Results, Financial Performance, Healthcare, Health Insurance, EPS Guidance, CMS Notice